XELOX +Bev +Tislelizumab for First-line Treatment of MSS/pMMR RAS-mutated mCRC

Abroad (travel likely)RecruitingPHASE2

Conditions

Tislelizumab · Bevacizumab · Oxaliplatin · Capecitabine · MSS/pMMR · Metastatic Colorectal Cancer (mCRC) · RAS-mutated · First-Line

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Lin Yang, Beijing, China
Contact: Study coordinator (lin yang) · linyangcicams@126.com · 13611267380

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy

Minimal Residual Disease · Adjuvant Chemotherapy · Colorectal Cancer

Abroad (travel likely)RecruitingPHASE2

Houston, United States

Nephron-sparing Treatment of Tislelizumab + Nab-Paclitaxel for Renal Pelvic Cancer

Renal Pelvic Carcinoma · Tislelizumab · PD-1 Inhibitor

Abroad (travel likely)RecruitingPHASE2

Tianjin, China

Combination of Concurrent Chemoradiotherapy With Surufatinib and Tislelizumab in Patients With Locally Advanced Non-Small Cell Lung Cancer

Surufatinib · Tislelizumab · Concurrent Chemoradiotherapy

Abroad (travel likely)RecruitingPHASE2

Guangzhou, China

Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments

Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer · Advanced Solid Tumors Harboring the KRAS G12C Mutation

Abroad (travel likely)RecruitingPHASE1, PHASE2

Sint-Niklaas, Belgium · Montreal, Canada